Cedera to Market New Imaging Technology

A unique imaging process known as functional diffusion mapping can be integrated into software systems for early detection of treatment response in cancer care.

The process has been licensed to Molecular Therapeutics (Ann Arbor, MI, USA). Cedara Software Corp. (Mississauga, Canada), a Merge Healthcare company (Milwaukee, WI, USA) and a leading independent developer of medical software technologies, has announced an exclusive relationship with Molecular Therapeutics in which Cedara will market and sell products based on this new technology for cancer-care assessment. While Cedara will focus on marketing the products to original equipment manufacturers (OEMs), Merge eMed will bring this technology to hospitals, imaging centers, and specialty clinics.

Unlike conventional methods utilized to monitor cancer treatment, functional diffusion mapping has the potential to evaluate the impact of anti-cancer drugs and radiation therapy on specific tumors through alterations in water diffusion and Brownian motion. In a breakthrough study published in the March 2005 issue of the Proceedings of the [U.S.] National Academy of Sciences, findings indicated that functional diffusion mapping may allow researchers to evaluate tumor response at a considerably earlier stage than is now possible.

"Armed with this kind of advanced early warning and response information, doctors, such as radiation therapy physicians, may be able to make more frequent and guided changes in the course of cancer treatment,” said Chris Barlow, director of business development, Cedara. "We hope that these changes will lead to better treatment and patient care.”




Related Links:
Cedara Software Corp.
Molecular Therapeutics
Merge Healthcare